Sangamo Therapeutics to Host First Quarter 2025 Earnings Conference Call

Sangamo Therapeutics to Release First Quarter 2025 Financial Results and Host Earnings Conference Call on May 12 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company developing transformative therapies using its proprietary platform technologies, announced today that it will…

Read MoreSangamo Therapeutics to Host First Quarter 2025 Earnings Conference Call

Chemed Corporation to Participate in the 2025 Bank of America Securities Health Care Conference

Chemed Corporation to Present at the 2025 Bank of America Securities Health Care Conference Chemed Corporation (NYSE: CHE), a leading publicly traded company with two nationally recognized subsidiaries, today announced its participation in the upcoming Bank of America Securities 2025…

Read MoreChemed Corporation to Participate in the 2025 Bank of America Securities Health Care Conference

Vasomune Therapeutics to Showcase Research at Leading Pulmonary Conference

Vasomune Therapeutics to Present Late-Breaking Research on AV-001 at the 2025 American Thoracic Society International Conference Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to address diseases driven by vascular dysfunction, today announced its participation in the 2025…

Read MoreVasomune Therapeutics to Showcase Research at Leading Pulmonary Conference

Harmony Biosciences Posts Strong Q1 2025 Results, Highlights Pipeline Progress and 2025 Outlook

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported robust financial and operational results for the first quarter of 2025, underscoring the company’s continued momentum and strategic focus on advancing its late-stage pipeline while reaffirming full-year revenue guidance. The company achieved a…

Read MoreHarmony Biosciences Posts Strong Q1 2025 Results, Highlights Pipeline Progress and 2025 Outlook

Fresenius Medical Care Delivers Robust Organic Growth in Revenue and Income in Q1 2025

Fresenius Medical Care Achieves Strong Start to 2025 with Solid Organic Growth and Improved Profitability Across Segments Fresenius Medical Care, the world’s leading provider of products and services for individuals with chronic kidney failure, began 2025 with a strong operational…

Read MoreFresenius Medical Care Delivers Robust Organic Growth in Revenue and Income in Q1 2025